Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome

 

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribute to the final pathway of inflammation that leads to CVD. MetS has gained significant importance recently due to the exponential increase in obesity worldwide. Early diagnosis is important in order to employ lifestyle and risk factor modification. Here, we review the epidemiology and pathogenesis of MetS, the role of inflammation in MetS, and summarize existing natural therapies for MetS.

  • Pathways and Mechanisms
  • Linkage and heredity associations
  • Insulin resistance and Glucose intolerance
  • Obesity and increased waist circumference
  • Dyslipidaemia and Hypertension
  • Etiology of endocrine disorders
  • Complications of diabetes mellitus
  • Associated autoimmune conditions

Related Conference of Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome

September 09-10, 2024

33rd International Diabetes and Healthcare Conference

Paris, France
September 09-10, 2024

7th Annual Meeting on Diabetes and Endocrinology

Paris, France
September 09-10, 2024

4th European Endocrinology and Diabetes Congress

Paris, France
September 25-26, 2024

5th World Summit on Diabetes Expo

Rome, Italy
October 14-15, 2024

3rd International Summit on Hormonal Disorders

Madrid, Spain
November 22-23, 2024

20th World Congress on Endocrinology & Diabetes

Amsterdam, Netherlands

Pathophysiology: Endocrinology, Diabetes and Metabolic Syndrome Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in